The effects of ethyl pyruvate against experimentally induced cisplatin ototoxicity in rats

References

• Akkoc H, Kelle I, Tunik S, Bahceci S, Sencar L, Ayaz E, Nergiz Y, Erdinc L, Erdinc M. 2012. Protective effect of ethyl pyruvate on liver injury in streptozotocin-induced diabetic rats. Acta Gastroenterol Belg. 75(3):336–341.
   PubMed Web of Science ®Google Scholar
• Akkoc H, Tunik S, Kelle I, Gurkan A, Erdogmus Z, Simsek S, Erdinc M. 2013. Ethyl pyruvate prevents ischemia reperfusion injury in isolated perfused rat heart. Lat Am J Pharm. 32(3):364–370.
   Web of Science ®Google Scholar
• Aksoy F, Dogan R, Ozturan O, Eren SB, Veyseller B, Pektas A, Huseyinbas O. 2014. Protective effect of trimetazidine on amikacin-induced ototoxicity in rats. Int J Pediatr Otorhinolaryngol. 78(4):663–669.
   PubMed Web of Science ®Google Scholar
• Bielefeld EC, Markle A, DeBacker JR, Harrison RT. 2018. Chronotolerance for cisplatin ototoxicity in the rat. Hear Res. 370:16–21.
   PubMed Web of Science ®Google Scholar
• Borse V, Al Aameri RFH, Sheehan K, Sheth S, Kaur T, Mukherjea D, Tupal S, Lowy M, Ghosh S, Dhukhwa A, et al. 2017. Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity. Cell Death Dis. 8(7):e2921.
   PubMedGoogle Scholar
• Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. 2000. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res. 144(1-2):135–146.
   PubMed Web of Science ®Google Scholar
• Chakhtoura M, Chain R, Varghese L, Gallucci S. 2014. Ethyl pyruvate, an inhibitor of high-mobility group box 1 (HMGB1) release, modulates dendritic cell activation and survival. J Immunol. 192.
   Web of Science ®Google Scholar
• De Freitas MR, Figueiredo AA, Brito GA, Leitao RF, Carvalho Junior JV, Gomes Junior RM, Ribeiro Rde A. 2009. The role of apoptosis in cisplatin-induced ototoxicity in rats. Braz J Otorhinolaryngol. 75(5):745–752.
   PubMedGoogle Scholar
• Fink MP. 2007. Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med. 261(4):349–362.
   PubMed Web of Science ®Google Scholar
• Hatzopoulos S, Di Stefano M, Albertin A, Martini A. 1999. Evaluation of cisplatin ototoxicity in a rat animal model. Ann N Y Acad Sci. 884:211–225.
   PubMed Web of Science ®Google Scholar
• Kaur T, Mukherjea D, Sheehan K, Jajoo S, Rybak LP, Ramkumar V. 2011. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis. 2:e180.
   PubMed Web of Science ®Google Scholar
• Kim HS, Cho IH, Kim JE, Shin YJ, Jeon JH, Kim Y, Yang YM, Lee KH, Lee JW, Lee WJ, et al. 2008. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic Biol Med. 45(7):950–963.
   PubMed Web of Science ®Google Scholar
• Kim J, Cho HJ, Sagong B, Kim SJ, Lee JT, So HS, Lee IK, Kim UK, Lee KY, Choo YS. 2014. Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Biochem Biophys Res Commun. 449(2):183–189.
   PubMed Web of Science ®Google Scholar
• Kim YM, Park EJ, Kim JH, Park SW, Kim HJ, Chang KC. 2016. Ethyl pyruvate inhibits the acetylation and release of HMGB1 via effects on SIRT1/STAT signaling in LPS-activated RAW264.7 cells and peritoneal macrophages. Int Immunopharmacol. 41:98–105.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. 2000. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res. 28(2):73–80.
   PubMed Web of Science ®Google Scholar
• Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT. 1997. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 123(9):978–981.
   PubMedGoogle Scholar
• Rybak LP, Husain K, Morris C, Whitworth C, Somani S. 2000. Effect of protective agents against cisplatin ototoxicity. Am J Otol. 21(4):513–520.
   PubMedGoogle Scholar
• Rybak LP, Ramkumar V. 2007. Ototoxicity. Kidney Int. 72(8):931–935.
   PubMed Web of Science ®Google Scholar
• Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. 2007. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 226(1-2):157–167.
   PubMed Web of Science ®Google Scholar
• Schmitt NC, Rubel EW, Nathanson NM. 2009. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci. 29(12):3843–3851.
   PubMed Web of Science ®Google Scholar
• Scott PM, Griffiths MV. 1994. A clinical review of ototoxicity. Clin Otolaryngol Allied Sci. 19(1):3–8.
   PubMed Web of Science ®Google Scholar
• Sheth S, Mukherjea D, Rybak LP, Ramkumar V. 2017. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 11:338.
   PubMed Web of Science ®Google Scholar
• Shin JH, Lee HK, Lee HB, Jin Y, Lee JK. 2014. Ethyl pyruvate inhibits HMGB1 phosphorylation and secretion in activated microglia and in the postischemic brain. Neurosci Lett. 558:159–163.
   PubMed Web of Science ®Google Scholar
• Sockalingam R, Freeman S, Cherny TL, Sohmer H. 2000. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol. 21(4):521–527.
   PubMedGoogle Scholar
• Somdas MA, Gunturk I, Balcioglu E, Avci D, Yazici C, Ozdamar S. 2020. Protective effect of N-acetylcysteine against cisplatin ototoxicity in rats: a study with hearing tests and scanning electron microscopy. Braz J Otorhinolaryngol. 86(1):30–37.
   PubMed Web of Science ®Google Scholar
• Teranishi M, Nakashima T, Wakabayashi T. 2001. Effects of alpha-tocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear Res. 151(1-2):61–70.
   PubMed Web of Science ®Google Scholar
• Varma SD, Hegde KR, Kovtun S. 2006. Oxidative damage to lens in culture: reversibility by pyruvate and ethyl pyruvate. Ophthalmologica. 220(1):52–57.
   PubMed Web of Science ®Google Scholar